Buscar en
Gastroenterología y Hepatología (English Edition)
Toda la web
Inicio Gastroenterología y Hepatología (English Edition) Immune thrombocytopenic purpura associated with Crohn's disease with complet...
Journal Information
Vol. 42. Issue 1.
Pages 37-38 (January 2019)
Vol. 42. Issue 1.
Pages 37-38 (January 2019)
Scientific letter
DOI: 10.1016/j.gastre.2018.01.006
Full text access
Immune thrombocytopenic purpura associated with Crohn's disease with complete response to infliximab
Púrpura trombocitopénica inmune asociada a enfermedad de Crohn con respuesta completa a infliximab
Visits
...
Eduard Bruneta, Montserrat Martínez de Solab, Pilar Garcia-Iglesiasa,
Corresponding author
pgarciai71@gmail.com

Corresponding author.
, Xavier Calveta
a Unidad de Gastroenterología, Servicio de Aparato Digestivo, Parc Taulí Hospital Universitari, Institut d’ Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain
b Servicio de Hematología, Parc Taulí Hospital Universitari, Institut d’ Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Characteristics of case reports.
Full Text

Immune thrombocytopenic purpura (ITP) is characterised by the production of autoantibodies against platelets, which are then destroyed by the mononuclear phagocyte system. In rare cases, ITP presents as an extraintestinal manifestation of inflammatory bowel disease (IBD), but few studies have explored its treatment in this context.1 We present the case of a patient with ITP secondary to Crohn's disease (CD) with complete response to treatment with anti-TNF.

This was a 55-year-old man with an unstudied history of diarrhoea with a frequency of 2–3 stools per day. In January 2016, during a routine company medical check-up, blood tests found a platelet count of 30,000/l with no bleeding diathesis and no other abnormalities. Suspecting ITP, the patient was started on corticosteroids (1.5mg/kg/day). The study was completed with viral serologies (HBV, HCV, HIV), H. pylori and autoimmunity, which were all negative. The patient's diarrhoea and thrombocytopenia improved, but reappeared after tapering the corticosteroids. A bone marrow study was performed, which showed normal cellularity, with an increase in the number of non-dysmorphic megakaryocytes. A CT of the chest and abdomen was performed which showed inflammation of the ileum. Colonoscopy confirmed multiple superficial ulcerations. Histology showed active chronic ileitis with no granulomas. The patient was diagnosed with non-fistulising ileal Crohn's disease with secondary ITP. In March 2016, azathioprine (AZA) was started, to which eltrombopag was added until control of IBD was achieved, postponing splenectomy. After two months, he presented with acute pancreatitis and AZA was discontinued. At follow-up, thrombocytopenia was poorly controlled (<30,000/l) and diarrhoea persisted. Accordingly, in July 2016, anti-TNF (infliximab 5mg/kg) was started. The patient's platelet count tripled after three weeks (from 21,000/l to 61,000/l), reaching 70,000/l at 12 weeks, which allowed corticosteroids to be withdrawn. By November 2016, the platelet count was over 100,000/l. We also observed improvement in CD, with resolution of diarrhoea (baseline Crohn's Disease Activity Index [CDAI] 251 and final CDAI 44) and evidence of mucosal healing in a colonoscopy performed in November 2016. Currently (January 2018) the patient is asymptomatic, with platelets >100,000/l and mucosal healing (18 months after starting infliximab).

IBD is chronic inflammation of the intestine caused by an immune system dysfunction with CD4 T cell-mediated Th1 immune response that stimulates production of INF-γ and TNF.2 In idiopathic ITP, a Th1 immune response with increased TNF also causes peripheral platelet destruction. Some authors have suggested that IBD may produce bacterial translocation, in which bacterial antigens pass into the bloodstream.3 This would trigger a Th1 immune response and synthesis of antibodies which, in rare cases, can cross-react against platelet antigens, giving rise to secondary ITP.4

Many different approaches to treating ITP secondary to IBD which are also useful in idiopathic ITP have been suggested1,3: steroids, gamma globulins, AZA, rituximab and splenectomy. Specifically, in non-responders, the use of anti-TNF for IBD and colectomy has been described in the case of ITP associated with ulcerative colitis.5 Another anti-TNF (etanercept) which is not effective in CD has been used successfully in refractory idiopathic ITP.6 Variations in the effectiveness of different anti-TNFs has been attributed to structural differences (for example, infliximab and adalimumab fix complement, but etanercept does not), which have a different modulatory effect on the immune response of Th1 cells.6,7

In order to verify the effect of anti-TNF in the treatment of ITP secondary to IBD, we conducted a systematic review of PubMed, Web of Science and SCOPUS databases for studies in adult populations published up to August 2017 in English and Spanish. The following MeSH terms were used: (“Crohn disease” OR “ulcerative colitis” OR “inflammatory bowel disease”) AND (“thrombocytopenic purpura” OR “thrombocytopenia”) AND (infliximab OR adalimumab OR anti-TNF). After screening for duplicates, 63 studies were identified. We chose seven articles; anti-TNF (infliximab) was used to treat CD and ITP in only two of these studies (Table 1).2,8 Response was positive in both cases.

Table 1.

Characteristics of case reports.

Author  Year  Age/gender  Duration of CD prior to ITP  Platelets at diagnosis  Medical treatment for CD  Medical treatment for ITP  Surgical treatment  Extent of CD  Platelets at end of treatment 
Germanidis et al.2  2007  69/female  15 days  8000/mcl  Corticosteroids azathioprine, metronidazole  Corticosteroids
Gamma globulin 
Ileocaecal resection  Ileocolic  199,000/l 
De Rossi et al.8  2008  41/male  10 years  36,800/mcl  Mesalazine, metronidazole, azathioprine, corticosteroids  Corticosteroids  Drainage of perianal abscess (1989 and 2001)
Right hemicolectomy with ileostomy 
Ileocolic, with part of the duodenum  72,000/l 

In conclusion, ITP is a rare extraintestinal manifestation of IBD which usually responds to conventional treatment. Biological anti-TNF agents (such as infliximab) can be effective in refractory cases.

References
[1]
M. Uzzan, L. Galicier, J.-M. Gornet, E. Oksenhendler, C. Fieschi, M. Allez, et al.
Autoimmune cytopenias associated with inflammatory bowel diseases: insights from a multicenter retrospective cohort.
Dig Liver Dis, 49 (2017), pp. 397-404
[2]
G. Germanidis, G. Lazaraki, S. Gintikas, D. Karayannis, K. Mikoudi, M. Sion.
Refractory Crohn-associated acute immune thrombocytopenic purpura treated with infliximab.
Eur J Intern Med, 18 (2007), pp. 344-346
[3]
W.G.N. Mares, J. Gerver, A.A.M. Masclee, M. Pierik.
Anti-TNF treatment of ulcerative colitis associated with idiopathic thrombocytopenic purpura.
Inflamm Bowel Dis, 17 (2011), pp. 864-865
[4]
G. Lazaraki, S. Metallidis, K. Giannoulis, A. Tarpagos, G. Germanidis.
Infliximab: an alternative treatment for refractory immune thrombocytopenic purpura related to Crohn's disease?.
Inflamm Bowel Dis, 13 (2007), pp. 1452-1453
[5]
S. Chandra, S. Finn, E. Obah.
Immune thrombocytopenic purpura in ulcerative colitis: a case report and systematic review.
J Community Hosp Intern Med Perspect, 4 (2014), pp. 23386
[6]
H. Zhong, J. Bussel, K. Yazdanbakhsh.
In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia.
Br J Haematol, 168 (2015), pp. 274-283
[7]
J.R. McMinn, S. Cohen, J. Moore, S. Lilly, J. Parkhurst, M.D. Tarantino, et al.
Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept.
Am J Hematol, 73 (2003), pp. 135-140
[8]
T.M. De Rossi, N. Krauss, R.E. Voll, A. Nägel, M. Weidenhiller, P.C. Konturek, et al.
Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
Digestion, 78 (2008), pp. 195-200

Please cite this article as: Brunet E, Martínez de Sola M, Garcia-Iglesias P, Calvet X. Púrpura trombocitopénica inmune asociada a enfermedad de Crohn con respuesta completa a infliximab. Gastroenterol Hepatol. 2019;42:37–38.

Copyright © 2018. Elsevier España, S.L.U.. All rights reserved
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos